Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Adherence to Lumefantrine-Artemether

This study has been completed.
Ifakara Health Research and Development Centre
Information provided by:
Centers for Disease Control and Prevention Identifier:
First received: September 8, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
This is a study of how well caregivers of children with malaria adhere to the recommended regimen for lumefantrine-artemether (LA). Children were randomly assigned to either a group receiving directly observed treatment in hospital or to a group treated at home by the routine caregiver (typically, patient's mother). Clinical/parasitologic, hematologic, pharmacologic and qualitative parameters were monitored over a 28-day follow-up period and are used to evaluate drug adherence.

Condition Intervention Phase
Malaria, Uncomplicated
Drug: artemether-lumefantrine
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Assessment of Adherence to a 6-Dose Regimen of Coartem for Treatment of Uncomplicated Malaria in Children Under 5 Years in Tanzania

Resource links provided by NLM:

Further study details as provided by Centers for Disease Control and Prevention:

Estimated Enrollment: 300
Study Start Date: August 2002
Estimated Study Completion Date: August 2006

Ages Eligible for Study:   up to 59 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • age < 5 years of age.
  • axillary temperature >= 37.5oC
  • unmixed infection with P. falciparum of between 1,000 and 250,000 asexual parasites/mm3 as determined by microscopic examination of thick, or thick and thin peripheral blood smears.
  • parent/guardian's informed consent and willingness to participate in the study

Exclusion criteria:

  • any evidence of severe or complicated malaria that would require hospitalization for treatment.
  • reported allergy to any antimalarial drugs, including artemisinin derivatives and sulfa drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00153491

Mkuranga District Hospital
Mkuranga, Mkuranga District, Tanzania
Sponsors and Collaborators
Centers for Disease Control and Prevention
Ifakara Health Research and Development Centre
Study Director: Louise Causer, MBBS, MScPH Centers for Disease Control and Prevention
Study Director: Salim Abdulla, MD, PhD Ifakara Health Research and Development Centre
Principal Investigator: Peter B Bloland, DVM, MPVM Centers for Disease Control and Prevention
Study Director: Stephen P Kachur, MD, MPH Centers for Disease Control and Prevention
  More Information

Additional Information: Identifier: NCT00153491     History of Changes
Other Study ID Numbers: CDC-NCID-3602
Study First Received: September 8, 2005
Last Updated: September 8, 2005

Keywords provided by Centers for Disease Control and Prevention:

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Artemether-lumefantrine combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antifungal Agents
Antiplatyhelmintic Agents
Anthelmintics processed this record on May 24, 2017